PT-141 (Bremelanotide): Dosage, Protocol, and Reconstitution Guide
Bremelanotide (PT-141)
Bremelanotide, also known as PT-141, is a melanocortin receptor agonist studied and prescribed for female sexual desire disorders. It works centrally rather than through direct vascular effects, which makes it distinct from PDE5-style medications.
How It Works
Melanocortin Receptor Activation → Brain Signaling Involved in Sexual Response → Desire / Arousal Support
Bremelanotide works through melanocortin receptors in the central nervous system, including MC4R-related pathways involved in sexual desire and response. Unlike medications that mainly affect blood flow, PT-141 works primarily through signaling in the brain.
Important Distinction
Bremelanotide (PT-141) is NOT a tanning peptide.
It does not work like Melanotan II and is not used for skin pigmentation.
Although both act on melanocortin receptors, PT-141 primarily affects the central nervous system.
Official branded product is supplied as a prefilled autoinjector rather than a reconstituted vial.
PT-141 (Bremelanotide) Protocol
On-Demand Use → Central Melanocortin Signaling → Desire / Arousal Support
Standard Setup
Vial
10 mg
Water
2.0 mL bacteriostatic water
Concentration
5 mg/mL
Conversion
1 unit = 50 mcg
FDA-Approved On-Demand Dose
On-Demand
Dose1.75 mg
Units35 units
Volume0.35 mL
TimingAt least 45 min before activity
FrequencyAs needed
Use Limits
MaximumNo more than 1 dose in 24 hours
Monthly LimitNo more than 8 doses per month
ReassessmentDiscontinue after 8 weeks if no meaningful benefit
Simple structure
PT-141 is not a daily-use peptide protocol. It is typically structured as an on-demand compound, used only when needed and limited by both daily and monthly maximums.
PT-141 is not a daily-use peptide protocol. It is typically structured as an on-demand compound, used only when needed and limited by both daily and monthly maximums.
Advanced / Educational Vial Conversion
Equivalent Dose Using Vial Example
Educational Conversion
Target Dose1.75 mg
Units35 units
Volume0.35 mL
Important:
Official branded product is supplied as a prefilled autoinjector rather than a reconstituted vial.
Official branded product is supplied as a prefilled autoinjector rather than a reconstituted vial.
How to Use Bremelanotide (Timing & Injection)
Use StyleOn-demand
TimingAt least 45 minutes before anticipated activity
RouteSubcutaneous injection
Repeat DosingDo not repeat within 24 hours
Injection Notes
Subcutaneous injection
Abdomen or thigh are standard sites
Use at least 45 minutes before anticipated activity
Do not repeat within the same 24-hour period
Rotate injection sites when using more than once across a month
Timing Notes
PT-141 is used situationally rather than continuously.
Allow enough lead time before anticipated activity.
Avoid using more frequently than recommended because nausea, flushing, blood pressure changes, or pigmentation changes may become more likely.
Reconstitution & Dosing (10 mg Vial)
Vial10 mg
Water2.0 mL
Concentration5 mg/mL
Conversion1 unit = 50 mcg
Dose Reference
10 units = 500 mcg (0.5 mg)
20 units = 1,000 mcg (1 mg)
35 units = 1,750 mcg (1.75 mg)
40 units = 2,000 mcg (2 mg)
Reconstitution Steps
Draw 2.0 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Allow powder to fully dissolve
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C
Long-term storage: freezing at −20°C is commonly preferred
Keep the vial sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Avoid leaving lyophilized peptide at room temperature for extended periods
Do not repeatedly freeze and thaw the same vial
Estimated Unmixed Shelf Life
Refrigerated (2–8°C): commonly ~12–24 months when sealed and dry
Frozen (−20°C): commonly up to ~2–3 years when stored properly
Actual stability depends on supplier quality, handling, and storage conditions
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C
Use within ~30 days
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Important distinction
FDA-approved bremelanotide is supplied as a ready-to-use prefilled autoinjector. Storage information for the approved product should not automatically be applied to lyophilized research vials.
FDA-approved bremelanotide is supplied as a ready-to-use prefilled autoinjector. Storage information for the approved product should not automatically be applied to lyophilized research vials.
Cycle Length & Time Between Cycles
On-Demand Use → Monthly Limit → 8-Week Reassessment → Continue or Stop
Standard Use Structure
Use StyleOn-demand
Daily LimitNo more than 1 dose in 24 hours
Monthly LimitNo more than 8 doses per month
Reassessment Point8 weeks
Time Between Uses
Minimum Gap24 hours between doses
Monthly SpacingDo not exceed 8 uses per month
Used only as needed rather than in a daily cycle
Reassess whether meaningful benefit occurs within 8 weeks
Stop after 8 weeks if symptoms have not improved
Why you may see different monthly limits in research:
The Phase 3 clinical trials allowed up to 12 doses per month. The FDA-approved prescribing recommendation is more conservative: no more than 8 doses per month and never more than one dose within 24 hours.
The Phase 3 clinical trials allowed up to 12 doses per month. The FDA-approved prescribing recommendation is more conservative: no more than 8 doses per month and never more than one dose within 24 hours.
When to Stop or Pause Early
Nausea is significant or repeated
Flushing, headache, or dizziness becomes uncomfortable
Blood pressure response is concerning
Skin hyperpigmentation appears or worsens
No meaningful benefit is seen by 8 weeks
What Human Studies Actually Used
Dose-Finding Research
Studied Doses
0.75 mg, 1.25 mg, and 1.75 mg
Route
Subcutaneous injection
Use Style
As needed
Phase 3 Research
Dose
1.75 mg
Timing
About 45 minutes before anticipated sexual activity
Study Length
24 weeks
What did the studies find?
In two large Phase 3 trials, women receiving bremelanotide reported greater improvements in sexual desire and less distress related to low sexual desire compared with placebo. Nausea, flushing, and headache were among the most commonly reported side effects.
In two large Phase 3 trials, women receiving bremelanotide reported greater improvements in sexual desire and less distress related to low sexual desire compared with placebo. Nausea, flushing, and headache were among the most commonly reported side effects.
Monitoring During Use
Nausea or flushing after injection
Blood pressure response
Injection site tolerance
Headache, dizziness, or fatigue
Possible skin hyperpigmentation with repeated use
Whether meaningful benefit occurs within 8 weeks
Benefits
On-demand use rather than daily dosing
Central mechanism different from PDE5 medications
May improve sexual desire and related distress
Convenient single-use dosing format in official product
Potential Side Effects
Nausea
Flushing
Injection site reactions
Headache
Transient blood pressure increase
Possible skin hyperpigmentation with repeated use
Stacking Strategies
On-Demand Use → Avoid Overlap → Monitor Nausea + Blood Pressure
Use Caution
Avoid layering with other agents that may worsen nausea or blood pressure changes
Avoid stacking with compounds that increase flushing, dizziness, or cardiovascular strain
Do not treat PT-141 like a daily stack peptide
Not a Typical Stack Peptide
Usually used standalone on demand
Best evaluated by response, tolerability, and whether meaningful benefit occurs
Avoid unnecessary add-ons when the goal is simple on-demand response
Lifestyle Support
Pair with sleep consistency
Support stress reduction
Consider relationship-focused interventions where appropriate
Track response across multiple uses rather than judging from one isolated attempt
Simple rule
PT-141 is best treated as a standalone, on-demand compound. Stacking should be cautious because nausea, flushing, and blood pressure response are already important monitoring points.
PT-141 is best treated as a standalone, on-demand compound. Stacking should be cautious because nausea, flushing, and blood pressure response are already important monitoring points.
Important Notes
Official indication is for acquired, generalized HSDD in premenopausal women
Not recommended in uncontrolled hypertension or known cardiovascular disease
Official product is a prefilled autoinjector, not a vial
Stop after 8 weeks if there is no improvement
No more than 1 dose in 24 hours
No more than 8 doses per month
PT-141 is not a tanning peptide and should not be confused with Melanotan II
Important Disclaimer
Bremelanotide is an FDA-approved prescription medication in branded form, but any non-branded vial-based use should be approached cautiously. This content is for educational purposes only.
Research & References
Primary Research
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction. Annals of the New York Academy of Sciences. 2003.
- Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the Safety, Pharmacokinetics and Pharmacodynamic Effects of Subcutaneously Administered PT-141, a Melanocortin Receptor Agonist, in Healthy Male Subjects and in Patients with an Inadequate Response to Viagra. International Journal of Impotence Research. 2004.
- Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist. Journal of Sexual Medicine. 2006.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019.
- FDA Prescribing Information for Vyleesi® (Bremelanotide Injection).
Research Note: Dosing and reconstitution details reflect the FDA-approved Vyleesi autoinjector protocol and common research-context handling practices. Clinical trial data for Bremelanotide are strongest in premenopausal women with HSDD; evidence for other populations and use cases remains more limited.
Comments
Post a Comment